Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.

Tomoaki Sonoda,Yukihiro Umeda,Yoshiki Demura,Toshihiko Tada,Koki Nakashima,Masaki Anzai,Makiko Yamaguchi,Akikazu Shimada, Masahiro Ohi,Chisato Honjo,Yuko Waseda,Masaya Akai,Tamotsu Ishizuka

Cancer medicine（2023）

引用 1|浏览14

暂无评分

摘要

Nab-paclitaxel therapy improved ORR after PD-(L)1 inhibitor treatment failure with a durable response of 13% and acceptable toxicities in patients with advanced NSCLC.

查看译文

关键词

immune checkpoint inhibitor,nab-paclitaxel,non-small cell lung cancer,programmed cell death 1 inhibitor,programmed death ligand 1 inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要